|
Product Information |
|
Product name |
Orforglipron hemicalcium hydrate; Orforglipron; Orforglipron calcium salt hydrate; Orforglipron monohydrate; Orforglipron hydrate |
|
CAS No. |
3008544-96-2 |
|
Molecular Formula |
C48H48F2N10O5.1/2Ca.H2O |
|
Molecular Weight |
921.02 |
|
Quality Standard |
99% up by HPLC |
|
Appearance |
White to off-white powder |
|
COA |
|
Test Items |
Specifications |
Results |
|
Appearance |
White to off-white powder |
White powder |
|
Solubility |
Freely soluble in Dimethyl sulfoxide , soluble in ethanol, practically insoluble in water |
Conforms |
|
Identification |
IR:The infrared absorption spectrum should be consistent with reference substance |
Conforms |
|
HPLC:The retention time of test sample major peak complies to reference substance |
Conforms |
|
|
Calcium salt Reaction for the Identification of calcium salts |
Conforms |
|
|
XRD: the characteristic diffraction peak 2θ at 6.8± 0.2 °、10.2±0.2°、11.9±0.2°、 14.0±0.2°、16.1±0.2 °、19.2±0.2° |
Conforms |
|
|
Related substances |
Impurity A ≤ 0.1% |
ND |
|
Any individual impurity ≤ 0.10% |
0.046% |
|
|
Total impurities ≤ 1.0% |
0.086% |
|
|
Purity ≥ 99% |
99.91% |
|
|
Enantiomer |
≤ 0.10% |
0.01% |
|
Calcium content |
1.8% - 2.5% |
2.24% |
|
Water |
4.0% - 7.0% |
5.32% |
|
PSD |
D90 ≤ 40μm |
15.51μm |
|
Heavy metals |
≤ 20ppm |
Conforms |
|
Residual solvents |
N,N-Dimethylformamide ≤ 0.088% |
ND |
|
Tetrahydrofuran ≤ 0.072% |
0.002% |
|
|
Ethyl acetate ≤ 0.5% |
0.015% |
|
|
Dichloromethane ≤ 0.06% |
ND |
|
|
Ethyl Alcoho ≤ 0.5% |
0.3% |
|
|
Microbial limit |
Aerobic bacteria ≤ 103cfu/g |
< 50 cfu/g |
|
Mold and yeast ≤ 102cfu/g |
< 50 cfu/g |
|
|
Escherichia coliNot detectable |
ND |
|
|
Assay (by HPLC) |
98.0%~102.0% |
100.21% |
|
Conclusion |
The product conforms to the specification |
|
|
Usage |
1. Product Overview
Orforglipron Hemicalcium Hydrate represents a breakthrough in metabolic therapeutics. It is a novel, non-peptide, small-molecule GLP-1 receptor agonist (GLP-1RA) currently under advanced investigation for Type 2 Diabetes (T2D) and chronic weight management. As a high-purity chemical intermediate, it serves as a critical building block for the next generation of oral anti-diabetic and anti-obesity formulations.
2. Key Competitive Advantages
(1) Oral Bioavailability: Unlike traditional peptide-based therapies (e.g., injectable Semaglutide), Orforglipron is a small molecule designed for convenient once-daily oral administration, eliminating injection-site reactions and cold-chain logistics.
(2) Dual Therapeutic Efficacy: Demonstrates significant clinical potential in both glycemic control and substantial body weight reduction, addressing two of the largest markets in pharmaceuticals.
(3) Non-Peptide Stability: As a synthetic small molecule, it offers superior chemical stability and scalability compared to complex biological peptides, ensuring consistent quality for mass production.
3. Target Indications
(1) Type 2 Diabetes Mellitus (T2D)
(2) Obesity & Overweight Management
(3) Metabolic Syndrome & Cardiovascular Health Research